Clinical pharmacology and therapeutics
-
Clin. Pharmacol. Ther. · Oct 1999
Randomized Controlled Trial Clinical TrialMeloxicam, 15 mg/day, spares platelet function in healthy volunteers.
To study the influence of meloxicam, a cyclooxygenase-2 (COX-2) preferential nonsteroidal anti-inflammatory drug, on serum thromboxane and platelet function in healthy volunteers with use of the maximum recommended daily dosage of 15 mg/day. ⋯ Meloxicam, 15 mg/day caused a major reduction of maximum thromboxane production but no reduction in collagen- or arachidonic acid-induced platelet aggregation and only minor increase of the closure time.